Natick-based medical device maker Boston Scientific Corp. said it will acquire Asthmatx Inc., a privately held California firm.
BSX will pay $193.5 million cash up front for Asthmatx and make additional contingency payments that could total $250 million by 2019. Those payments are subject to the achievement of certain revenue criteria.
The transaction is expected to close in the fourth quarter.
Asthmatx makes catheter-based devices for adults with asthma that is not well-controlled.
In a statement, Ray Elliott, BSX’s president and CEO, said the acquisition is “an important step in the execution of our strategy to realign Boston Scientific’s portfolio.”
Asthmatx’s catheter-based bronchial thermoplasty procedure was approved by the U.S. Food and Drug Administration last spring.
